Beam Therapeutics (BEAM) closed at $24.19 on Oct 19, 2026, up 3.1% on the day. The stock is down 3.0% over the past month, down 11.4% over three months, down 12.7% year to date and down 6.2% over the past year. It trades 36.8% below its 52-week high of $38.26 and 19.6% above its 52-week low of $20.23. The close sits below its 50-day moving average ($26.20) and below its 200-day moving average ($28.33).
NextPick tracks BEAM in its Cell / Gene Therapy basket alongside CRSP, VCEL, NTLA, PRME and EDIT. As of Oct 19, 2026, the basket's money-flow score is -18 (weak outflow), and the basket is down 4.8% over five sessions. Over the past month BEAM ranks 3rd of 7 basket members by price change.
Over its last 8 reports the stock moved an average of 4.8% on the first trading day after earnings, beating the options-implied move in 1 of 6.
Over the last 8 reports, BEAM moved an average of 4.8% on the first trading day after earnings. The move beat the options-implied move in 1 of 6 reports.
No — the Oct 19, 2026 close of $24.19 is 14.6% below the 200-day average of $28.33.
BEAM closed 36.8% below its 52-week high of $38.26.
NextPick groups BEAM with CRSP, VCEL, NTLA, PRME and EDIT in its Cell / Gene Therapy basket.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
